3SBio Inc - Company Profile
Powered by
All the data and insights you need on 3SBio Inc in one report.
- Save hours of research time and resources with
our up-to-date 3SBio Inc Strategy Report
- Understand 3SBio Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
3SBio Inc (3SBio) is a biotechnology company that discovers, develops, manufactures and markets biopharmaceutical products. The company develops recombinant or genetically engineered, protein-based products and other pharmaceutical product candidates to meet significant unmet medical needs in the areas of cancer and its supportive care, nephrology, dermatology, and other disease conditions. The company distributes its products to hospitals, clinics and dialysis centers in China. The company sells its products in Colombia, Brazil, Costa Rica, Egypt, Dominican Republic, Guatemala, El Salvador, Mongolia, Laos, Pakistan, Sri Lanka, Myanmar, the Philippines, Paraguay, Thailand, Trinidad and Tobago. 3SBio is headquartered in Shenyang, Liaoning, China.
3SBio Inc premium industry data and analytics
Products and Services
Products | Services | Brands |
---|---|---|
Oncology: | Service: | EPIAO |
TPIAO | CDMO | Cipterbin |
Cipterbin | TPIAO | |
XYZ | XYZ | |
XYZ | XYZ | |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Regulatory Approval | In January, Zhejiang Wansheng Pharmaceutical Co., Ltd received approval from the National Medical Products Administration by the PRC to launch Mandi (5% minoxidil) Foam for the treatment of androgenetic alopecia and alopecia areata. |
2023 | Contracts/Agreements | In November, Shenyang 3SBio Co. and CStone Pharmaceuticals signed a license agreement and a production technology transfer agreement to obtain the anti-PD-1 monoclonal antibody nofazinlimab (CS1003) independently developed by CStone Pharmaceuticals in mainland China. |
2023 | Regulatory Approval | In July, the company received New Drug Application (NDA) approval for Nafurafine Hydrochloride Orally Disintegrating Tablets. |
Competitor Comparison
Key Parameters | 3SBio Inc | Kexing Biopharm Co Ltd | Hubei Guangji Pharmaceutical Co Ltd | CapitalBio Corp | China Intertrade Ltd |
---|---|---|---|---|---|
Headquarters | China | China | China | China | China |
City | Shenyang | Ji'Nan | Huanggang | Beijing | Shanghai |
State/Province | Liaoning | Shandong | Hubei | Beijing | Shanghai |
No. of Employees | 5,411 | 1,407 | 1,256 | - | - |
Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Lou Jing | Executive Director; Chief Executive Officer; Chairman | Executive Board | 2014 | 60 |
He Xiang | Chief Financial Officer | Senior Management | 2023 | - |
Zhenping Zhu, M.D., Ph.D | President - Research & Development; Chief Scientific Officer | Senior Management | 2017 | 58 |
Su Dongmei | Senior Vice President; Director | Executive Board | 2014 | 53 |
Ji Zhang | Vice President | Senior Management | 2016 | 65 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer